GLP-1 receptor agonists have demonstrated glycaemic control, cardiovascular benefits in certain patient populations and significant weight reduction effects
therefore, the number of participants treated with SGLT2is within this post hoc analysis is low, and higher number of patients were treated with -glucosidase inhibitors, sulfonylureas, and other drugs that do not reflect current real-world practice
Allulose is shown to boost the production of GLP-1 (glucagon-like peptide-1), PYY (peptide YY), and CCK (cholecystokinin)
The question of whether semaglutide can be administered every other week rather than weekly is not supported by current FDA labeling or clinical trial evidence
31WardAAlvarezPVoL
Several studies have shown that metformin also lowers cholesterol levels, TG, LDL-cholesterol and HDL-cholesterol